Arvinas Inc (NASDAQ:ARVN)

43.17
Delayed Data
As of May 27
 +1.87 / +4.53%
Today’s Change
37.41
Today|||52-Week Range
108.47
-47.44%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.4B

Company Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Contact Information

Arvinas, Inc.
5 Science Park
New Haven Connecticut 06511
P:(203) 535-1456
Investor Relations:

Employees

Shareholders

Mutual fund holders49.08%
Other institutional38.22%
Individual stakeholders35.71%

Top Executives

John G. HoustonPresident, Chief Executive Officer & Director
Sean A. CassidyChief Financial Officer
Ian TaylorChief Scientific Officer
Ronald PeckChief Medical Officer
Kimberly WehgerVP-Information Technology & Corporate Projects